Surgery for patients with persistent pathological N2 IIIA stage in non-small-cell lung cancer after induction radio-chemotherapy: The microscopic seed of doubt

European Journal of Cardio-thoracic Surgery

Volumn 40, Issue 3, 2011, Pages 656-663

  Meacci, Elisa ^a   Cesario, Alfredo ^b,c   Cusumano, Giacomo ^a   Lococo, Filippo ^a   D'Angelillo, Rolando ^c   Dall'Armi, Valentina ^b   Margaritora, Stefano ^a   Granone, Pierluigi ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Induction therapy; NSCLC; Radiotherapy; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUOROURACIL; GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BILOBECTOMY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIMODALITY CANCER THERAPY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY, ADJUVANT; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PNEUMONECTOMY; RECURRENCE; TREATMENT OUTCOME;

EID: 80051560924     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1016/j.ejcts.2010.12.062     Document Type: Article

References (25)

1. Trodella L., Granone P., Valente S., Margaritora S., Macis G., Cesario A., D'Angelillo R.M., Valentini V., Corbo G.M., Porziella V., Ramella S., Tonini G., Galetta D., Ciresa M., Vincenzi B., Cellini N. Neoadjuvant concurrent radiochemotherapy in locally advanced (IIIA-IIIB) non small cell lung cancer: long term results according to downstaging. Ann Oncol 2004, 15(3):389-398.
2. Bueno R., Richards W.G., Swanson S.J., Jaklitsch M.T., Lukanich J.M., Mentzer S.J., Sugarbaker D.J. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 2000, 70:1826-1831.
3. Port J.L., Korst R.J., Lee P.C., Levin M.A., Becker D.E., Keresztes R., Altorki N. Surgical resection for residual N2 disease after induction chemotherapy. Ann Thorac Surg 2005, 79:1686-1690.
4. Margaritora S., Cesario A., Galetta D., D'Andrilli A., Macis G., Mantini G., Trodella L., Granone P. Ten year experience with induction therapy in locally advanced non small cell lung cancer (NSCLC): is clinical re-staging predictive of pathologic staging?. Eur J Cardiothorac Surg 2001, 19:894-898.
5. Dooms C., Verbeken E., Stroobants S., Nackaerts K., De Leyn P., Vansteenkiste J. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol 2008, 26(7):1128-1134.
6. Cerfolio R.J., Maniscalco L., Bryant A.S. The treatment of patients with stage IIIa non-small cell lung cancer from N2 disease: who returns to the surgical arena and who survives. Ann Thorac Surg 2008, 86(3):912-920.
7. Cafarotti S., Cesario A., Cusumano G., Granone P. Single station N2 NSCLC: a brief reflection on possible overdoing. Ann Thorac Surg 2009 Dec 1, 88(6):2069-2070.
8. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
9. Lardinois D., De Leyn P., Van Schil P., Porta R.R., Waller D., Passlick B., Zielinski M., Lerut T., Weder W. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006 Nov 1, 30(5):787-792.
10. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 1997, 111:1710-1717.
11. Junker K., Thomas M., Schulmann K., Klinke F., Bosse U., Müller K.M. Tumour regression in non-small cell lung cancer following neoadjuvant therapy: histological assessment. J Cancer Res Clin Oncol 1997, 123:469-477.
12. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., Demedts M.G. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Ann Thorac Surg 1997, 63(5):1441-1450. Leuven Lung Cancer Group.
13. Robinson L.A., Ruckdeschel J.C., Wagner H., Stevens C.W. Treatment of non-small cell lung cancer-stage IIIA. ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:243S-265S.
14. Farray D., Mirkovic N., Albain K.S. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol 2005, 23:3257-3269.
15. Eberhardt W.E., Albain K.S., Pass H., Putnam J.B., Gregor A., Assamura H., Mornex F., Senan S., Belderbos J., Westeel V., Thomas M., Van Schil P., Vansteenkiste J., Manegold C., Mirimanoff R.O., Stuschke M., Pignon J., Rocmans P., Shepherd F.A. Induction treatment before surgery for non-small cell lung cancer: IASLC consensus report. Lung Cancer 2003, 42:S9-14.
16. Albain K.S., Swann R.S., Rusch V.W., Turrisi A.T., Shepherd F.A., Smith C., Chen Y., Livingston R.B., Feins R.H., Gandara D.R., Fry W.A., Darling G., Johnson D.H., Green M.R., Miller R.C., Ley J., Sause W.T., Cox J.D. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009, 374:379-386.
17. Lorent N., De Leyn P., Lievens Y., Verbeken E., Nackaerts K., Dooms C., Van Raemdonck D., Anrys B., Vansteenkiste J. Long-term survival of surgically staged IIIA-N2 non-small-cell lung cancer treated with surgical combined modality approach: analysis of a 7-year prospective experience. Ann Oncol 2004, 15:1645-1653. Leuven Lung Cancer Group.
18. Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., Schmid R.A., Pless M., Habicht J., Roth A.D., Spiliopoulos A., Stahel R., Weder W., Stupp R., Egli F., Furrer M., Honegger H., Wernli M., Cerny T., Ris H.B. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA PN2NSCLC: a multicenter phase II trial. J Clin Oncol 2003, 21(9):1752-1759.
19. Eberhardt W., Wilke H., Stamatis G., Stuschke M., Harstrick A., Menker H., Krause B., Müeller M.R., Stahl M., Flasshove M., Budach V., Greschuchna D., Konietzko N., Sack H. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998, 16(2):622-634.
20. Martini N., Kris M.G., Flehinger B.J., Gralla R.J., Bains M.S., Burt M.E., Heelan R., McCormack P.M., Pisters K.M., Rigas J.R. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993, 55:1365-1374.
21. Elias A.D., Skarin A.T., Leong T., Mentzer S., Strauss G., Lynch T., Shulman L., Jacobs C., Abner A., Baldini E.H. Neoadjuvant treatment of stage IIIA non-small cell lung cancer. Long-term results. Am J Clin Oncol 1994, 17:26-36.
22. Rusch V.W., Crowley J., Giroux D.J., Goldstraw P., Im J., Tsuboi M., Tsuchiya R., Vansteenkiste J. The IASLC lung cancer staging project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 2007, 2(7):603-612.
23. Mansour Z., Kochetkova E.A., Santelmo N., Ducrocq X., Quoix E., Wihlm J.M., Massard G Persistent N2 disease after induction therapy does not jeopardize early and medium term outcomes of pneumonectomy. Ann Thorac Surg 2008, 86:228-233.
24. Cesario A., Ferri L., Galetta D., Pasqua F., Bonassi S., Clini E., Biscione G., Cardaci V., Di Toro S., Zarzana A., Margaritora S., Piraino A., Russo P., Sterzi S., Granone P. Post-operative respiratory rehabilitation after lung resection for non-small cell lung cancer. Lung Cancer 2007, 57:175-180.
25. Decaluwé H., De Leyn P., Vansteenkiste J., Dooms C., Van Raemdonck D., Nafteux P., Coosemans W., Lerut T. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival. Eur J Cardiothorac Surg 2009, 36:433-439.